|
HY-W035376-250mg
|
MedChemexpress LLC
|
m-PEG6-CH2CH2CHO [CAS 1058691-77-2]
|
|
Cancer-programmed cell death
|
|
|
HY-W035376-50mg
|
MedChemexpress LLC
|
m-PEG6-CH2CH2CHO [CAS 1058691-77-2]
|
|
Cancer-programmed cell death
|
|
|
HY-133066-100mg
|
MedChemexpress LLC
|
m-PEG6-NHS ester [CAS 1449390-12-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-133066-250mg
|
MedChemexpress LLC
|
m-PEG6-NHS ester [CAS 1449390-12-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-133066-50mg
|
MedChemexpress LLC
|
m-PEG6-NHS ester [CAS 1449390-12-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-120237-100mg
|
MedChemexpress LLC
|
m-PEG7-Amine [CAS 170572-38-0]
|
|
Cancer-programmed cell death
|
|
|
HY-120237-25mg
|
MedChemexpress LLC
|
m-PEG7-Amine [CAS 170572-38-0]
|
|
Cancer-programmed cell death
|
|
|
HY-120237-50mg
|
MedChemexpress LLC
|
m-PEG7-Amine [CAS 170572-38-0]
|
|
Cancer-programmed cell death
|
|
|
HY-130151-100mg
|
MedChemexpress LLC
|
m-PEG7-CH2CH2COOH [CAS 1093647-41-6]
|
|
Cancer-programmed cell death
|
|
|
HY-130151-50mg
|
MedChemexpress LLC
|
m-PEG7-CH2CH2COOH [CAS 1093647-41-6]
|
|
Cancer-programmed cell death
|
|
|
HY-W040236-100mg
|
MedChemexpress LLC
|
m-PEG8-Amine [CAS 869718-81-0]
|
|
Cancer-programmed cell death
|
|
|
HY-W040236-50mg
|
MedChemexpress LLC
|
m-PEG8-Amine [CAS 869718-81-0]
|
|
Cancer-programmed cell death
|
|
|
HY-W040236-500mg
|
MedChemexpress LLC
|
m-PEG8-Amine [CAS 869718-81-0]
|
|
Cancer-programmed cell death
|
|
|
HY-W019793-100mg
|
MedChemexpress LLC
|
m-PEG8-NHS ester [CAS 756525-90-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-W019793-50mg
|
MedChemexpress LLC
|
m-PEG8-NHS ester [CAS 756525-90-3]
|
|
COVID-19-immunoregulation
|
|
